Meet Christelle Huguet
Executive Vice President, Research & Development
“I came to science because I was curious – I loved asking questions and finding answers in the data. It’s not always smooth, but the challenges are worth it when you know the goal is helping people. We’re all patients at some point. Using science to make a difference, whether today or tomorrow, is a privilege that motivates me every day.”?
Learn More About Christelle Huguet
Meet Sandra Silvestri
Executive Vice President, Chief Medical Officer
“What drives me is the opportunity to shape medicine and clinical practice that reaches beyond the individual – to improve out comes for entire communities. As a physician, I’ve seen the difference the right treatment and appropriate care can make. Now, I have the privilege of helping to shape clinical practice and bring those treatments to more people,faster than ever before.” ?
Learn More About Sandra SilvestriEMC易倍官网入口 – （中国大陆）官方网站 - EMC体育
What is it like to work at the forefront of innovation?? ?
From lab discoveries to patient impact, hear directly from the people making it happen. Explore stories from our global R&D and medical teams – and see how purpose drives every step of the journey.
16 March 2026
A Life in Science: The role of data in advancing medicines
11 March 2026
A Life in Science: Shaping early development with patient focus
04 March 2026
A Life in Science: Curiosity and collaboration in cancer research
18 February 2026
A Life in Science: Adapting science through diverse perspectives
11 February 2026
A Life in Science: Teamwork and resilience in early development?
10 March 2025
A Life in Science: Driving Innovation Through Collaboration?
17 February 2025
A Life in Science: Following Passions to Transform Healthcare??
24 February 2025
A Life in Science: Navigating Uncertainty to Make a Difference?
17 March 2025
A Life in Science: Shaping the Future of Precision Medicine?
03 March 2025
A Life in Science: The Privilege of Making a Difference?
EMC易倍官网入口 – （中国大陆）官方网站 - EMC体育
Strategic?Focus: Alexis?Cocozaki?on the?pathway to early?discovery at Ipsen??
At the heart of Ipsen’s early discovery efforts is a question of fit—how a molecule interacts with a disease-relevant protein, and what that means for therapeutic potential. Alexis?Cocozaki’s?team focuses on that exact space, applying biophysical and structural biology techniques to evaluate and?optimize?new assets at the atomic level.?
From culture to clinic: Alison Mason on making science work at scale?
The science behind cell culture and fermentation rarely makes headlines. But without it, no treatment would reach a patient. Alison Mason knows this better than most.
Defining the path: Lineu Domit on the role of safety in early development
Before a medicine reaches patients, its promise must be measured against its risks. For Lineu Domit, safety physician in Ipsen’s Global Patient Safety team, this balance is the essence of early development.
Bridging science and leadership: Elisabetta Leo on guiding early development at Ipsen
Elisabetta Leo is moving science forward at the heart of early development. This involves progressing nonclinical data and novel molecules in oncology, from bench to bedside.
Designing for precision: A passion for innovation with Will Olughu
Developing an antibody-drug conjugate (ADC) is a technical challenge. Across Ipsen’s work in ADCs Will Olughu leads a team driving the chemistry, manufacturing, and controls (CMC) effort to bring this complex science into reality.
Built to endure: Prince Korah on relentless pursuit of robust drug product development.
Robustness is not a box to check—it’s the foundation of every decision. As a Senior Director in the Pharmaceutical Development function in Ipsen’s drug product development team, Prince Korah focuses on driving the pharmaceutical development strategy by overseeing the end-to-end life cycle of drug products with his team.
Targeting what cannot be seen: Lindsey Rodrigues on the complexity of epigenetics
Targeting what cannot be seen: Lindsey Rodrigues on the complexity of epigenetics or mutated in a particular cancer. We have to ask, ‘do we have an understanding of how this gene works? Can we design a medicine to treat it or to target it?”’
Building better processes, earlier: a chemist’s perspective on innovation and sustainability
Nathan McCormack focuses on the earliest stages of active pharmaceutical ingredient (API) development.
EMC易倍官网入口 – （中国大陆）官方网站 - EMC体育
Philippe Lopes-Fernandes, EVP, Chief Business Officer on how true collaboration paves the way to innovation.
EMC易倍官网入口 – （中国大陆）官方网站 - EMC体育
Christelle Huguet, EVP, Head of Research and Development on harnessing technology to accelerate the journey from discovery to innovative medicine.
Partnering
Our people are the heart of our science, but innovation happens through collaboration. Ipsen’s partnerships span from basic research to clinical development, working with external partners to unlock new possibilities. ?
EMC易倍官网入口 – （中国大陆）官方网站 - EMC体育 Learn more